Akigajeong 100/500 milligrams
Niraparib Tosylate Monohydrate 159.4mg · Abiraterone Acetate Micronized 500mg
Tablet · Prescription medication · Combination
Korea Janssen Co., Ltd.
MFDS item code 202302817 · Approved 2023.09.25
Combination treatment for BRCA-mutated metastatic castration-resistant prostate cancer
This medication is used in combination with prednisolone for adult patients with metastatic castration-resistant prostate cancer who have not experienced chemotherapy treatment. It primarily helps to slow the progression of prostate cancer and improve the patient's condition. Patients are advised to understand that this treatment is used to inhibit the growth of cancer cells and effectively manage the progression of the disease. This combination therapy is suitable for those lacking treatment experience and is designed to maximize therapeutic efficacy. Overall, this drug has a positive impact on the treatment of prostate cancer.
The recommended dose of this medicine is niraparib 200mg / abiraterone acetate 1000mg (2 tablets of 100mg/500mg), administered once daily, at approximately the same time each day whenever possible. This medicine must be taken on an empty stomach. It should be taken at least 2 hours after a meal, and no food should be consumed for at least 1 hour after taking it. Swallow the tablets whole with water; do not chew, break, or crush them (see Precautions for Use, 14. Information for Healthcare Professionals, 1) Pharmacokinetic Information, (1) Absorption). Prednisolone dose This medicine is used in combination with prednisolone 10mg once daily. When this medicine is administered in combination with prednisolone to patients with metastatic castration-resistant prostate cancer with BRCA gene mutations, confirm that the patient is positive for a BRCA gene mutation. For the diagnostic method used in the clinical trial, see “Precautions for Use, section 5. General Precautions.” Missed doses If a dose of this medicine or prednisolone is missed, take it as soon as possible on the same day, and resume the regular schedule starting the following day. Do not take an additional dose to make up for the missed dose. Duration of treatment Treatment should continue until disease progression or unacceptable toxicity occurs. Dose adjustment ⋅ Nonhematologic adverse reactions In patients who experience grade 3 or higher nonhematologic adverse reactions, treatment should be temporarily interrupted and appropriate medical management initiated (see Precautions for Use). Treatment with this medicine should not be resumed until the toxic symptoms have resolved to grade 1 or baseline. ⋅ Hematologic adverse reactions In patients who experience grade 3 or higher or intolerable hematologic toxicity, consider temporarily interrupting this medicine and providing supportive care rather than permanently discontinuing it. If the hematologic toxicity does not recover to an acceptable level within 28 days of the treatment interruption, permanently discontinue this medicine. Dose adjustment recommendations for thrombocytopenia and neutropenia are listed in Table 1. Table 1. Dose adjustment recommendations for thrombocytopenia and neutropenia Grade 1 No change; consider monitoring weekly. Grade 2 Monitor at least weekly and consider withholding this medicine until recovery to grade 1 or baseline. 1 Weekly monitoring is recommended for 28 days after resuming this medicine. Grade 3 or higher Consider withholding this medicine until platelet and neutrophil counts recover to grade 1 or baseline1 (monitor at least weekly). Then resume treatment with this medicine or, if necessary, administer 2 lower-strength tablets (50mg/500mg). Weekly blood count monitoring is recommended for 28 days after resuming treatment. Second occurrence of grade 3 or higher Withhold this medicine and monitor at least weekly until platelet and/or neutrophil counts recover to grade 1. When treatment is resumed, start with 2 lower-strength tablets (50mg/500mg). Weekly monitoring is recommended for 28 days after resuming treatment with this medicine. If the patient was already receiving the lower-strength tablets of this medicine (50mg/500mg), consider discontinuing treatment. Third occurrence of grade 3 or higher Permanently discontinue this medicine. 1 During a temporary interruption of treatment with this medicine, healthcare professionals may consider and administer abiraterone acetate and prednisone or prednisolone to maintain the daily dose of abiraterone acetate (see the prescribing information for abiraterone acetate). Treatment with this medicine may be resumed only when toxicity due to thrombocytopenia and neutropenia improves to grade 1 or returns to baseline. If necessary, treatment may be resumed with the lower dose of this medicine, 50mg/500mg (2 tablets). For the most common adverse reactions, see Precautions for Use, section 4. Adverse Reactions. For grade 3 or higher anemia, temporarily interrupt this medicine and manage with supportive care until recovery to grade 2 or lower. If anemia persists, consider dose reduction (2 tablets of 50mg/500mg) based on clinical judgment. Table 2. Dose adjustment recommendations for anemia Grade 1 No change; consider monitoring once weekly. Grade 2 If baseline anemia is grade 1 or lower, monitor at least once weekly for 28 days. Grade 3 or higher Withhold this medicine1 and provide supportive care with monitoring at least once weekly until recovery to grade 2 or lower. If anemia persists, consider dose reduction (2 tablets of 50mg/500mg) based on clinical judgment. Second occurrence of grade 3 or higher Withhold this medicine and provide supportive care with monitoring at least once weekly until recovery to grade 2 or lower. When treatment is resumed, start with 2 lower-strength tablets (50mg/500mg tablets). Weekly monitoring is recommended for 28 days after resuming treatment with this medicine. If the patient was already receiving the lower-strength tablets of this medicine (50mg/500mg), consider discontinuing treatment. Third occurrence of grade 3 or higher Consider discontinuing treatment with this medicine based on clinical judgment. 1 During a temporary interruption of treatment with this medicine, healthcare professionals may consider and administer abiraterone acetate and prednisone or prednisolone to maintain the daily dose of abiraterone acetate (see the prescribing information for abiraterone acetate). Recommended monitoring A complete blood count should be obtained before starting treatment and monitored weekly during the first month, every 2 weeks for the next 2 months, monthly for the remainder of the first year, and every 2 months thereafter during treatment to monitor for clinically significant changes in hematologic parameters (see Precautions for Use). Serum aminotransferases and total bilirubin should be measured before starting treatment, every 2 weeks during the first 3 months of treatment, monthly for the remainder of the first year, and every 2 months thereafter during treatment. Serum potassium should be monitored monthly during the first year of treatment and every 2 months thereafter (see Precautions for Use). Blood pressure should be monitored weekly for the first 2 months, monthly for the first year, and every 2 months thereafter during treatment. Hepatic impairment This medicine should not be administered to patients with moderate to severe hepatic impairment (see 14. Information for Healthcare Professionals – 1) Pharmacokinetic Information – (5) Special Populations). Hepatotoxicity In patients who develop grade 3 or higher hepatotoxicity (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] increased to 5 times or more the upper limit of normal [ULN]) or total bilirubin greater than 3 times the ULN, temporarily interrupt treatment with this medicine and closely monitor liver function (see Precautions for Use). If severe hepatotoxicity (ALT or AST at 20 times the ULN) develops while the patient is receiving this medicine, treatment should be permanently discontinued. Permanently discontinue this medicine in patients with ALT greater than 3 times the ULN and total bilirubin greater than 2 times the ULN in the absence of biliary obstruction or other causes of concurrent elevations (see Precautions for Use). Renal impairment No dose adjustment is required for patients with mild to moderate renal impairment. Use of this medicine is not recommended in patients with severe renal impairment, as it has not been studied in this population (see 14. Information for Healthcare Professionals – 1) Pharmacokinetic Information – (5) Special Populations).
This medication may lead to the development of severe hematological malignancies such as myelodysplastic syndrome or acute myeloid leukemia; therefore, consultation with a specialist is required if hematological toxicity is suspected. Patients with allergies to this medication or its additives, pregnant or breastfeeding women, patients with moderate or severe hepatic impairment, and lactose intolerant patients should not use this drug. Additionally, concomitant use with radium-223 chloride is not recommended. Patients with hypertension, hypokalemia, fluid retention, or cardiovascular disease should take this drug with caution, and those with severe renal impairment should also use this medication carefully. Common side effects may include anemia, constipation, hypertension, nausea, fatigue, and thrombocytopenia, so symptoms should be closely monitored during treatment. Particularly, blood-related adverse reactions such as anemia and thrombocytopenia, as well as neutropenia, often occur, necessitating regular blood tests. In cases of severe hypertension, blood pressure should be controlled prior to treatment and monitored frequently during treatment. Patients with weakened heart function may experience cardiovascular adverse reactions such as heart failure or arrhythmias, so careful monitoring is needed. Liver function impairment may also occur; therefore, routine liver function tests should be conducted before and during treatment, and if liver function deteriorates severely, treatment should be discontinued. There may be an increased risk of infection, so if any infection symptoms appear, the healthcare provider should be notified immediately. There is a risk of thromboembolic events such as pulmonary embolism, requiring prompt assessment and treatment if associated symptoms arise. This medication should be taken at least 2 hours after eating, and eating should be avoided for at least 1 hour after taking it. Due to many drug interactions, any other medications being taken must be discussed with a healthcare provider. Pregnant women, women who might become pregnant, and breastfeeding mothers should not handle or take this medication, and effective contraception is required during and after treatment for a certain period. Safety and efficacy in children have not been established, and no dosage adjustment is required for the elderly. In the case of overdose, there is no specific antidote, and treatment should be given according to symptoms, with caution needed while driving or operating machinery. This medication should be stored out of the reach of children and kept in its original container to maintain quality.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly sealed container to avoid exposure to air and moisture, ideally at a temperature between 1 and 30 degrees Celsius. This will help maintain the drug's efficacy.
Orange oval film-coated tablets
56 tablets/box [28 tablets/PTP x 2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Niraparib Tosylate Monohydrate 159.4mg · Abiraterone Acetate Micronized 500mg
Tablet · Prescription medication · Combination
Korea Janssen Co., Ltd.
Niraparib Tosylate Monohydrate 79.7mg · Abiraterone Acetate Micronized 500mg
Tablet · Prescription medication · Combination
Korea Janssen Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.